Publications

Preclinical
AACR
April 17, 2026
Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads
Petersen et al.
Preclinical, ZW191
AACR
April 17, 2026
ZW191 – a differentiated FRα-targeted topoisomerase I antibody-drug conjugate active in combination with standard of care drugs
Lawn et al.
Preclinical
Bioconjugate Chemistry
March 31, 2026
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo
Hernández Rojas et al.
Preclinical
ESMO TAT
March 18, 2026
Engineering trispecific and multivalent molecules: Design for selectivity and potency
Nina Weisser, Ph.D.
Preclinical
ADC Asia
March 11, 2026
Enhancing the therapeutic potential of topoisomerase 1 inhibitor ADCs: from concept to clinic
Paul Moore, Ph.D.
Preclinical
Festival of Biologics
March 5, 2026
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Robert Nechanitzky
Preclinical
Festival of Biologics
March 4, 2026
Engineering Next-Generation T Cell Engagers: A Trispecific Platform for Cancer Immunotherapy
Anna von Rossum, Ph.D.
Preclinical, ZW191
World ADC London
February 25, 2026
Design of ZW191: Preclinical Insights and Clinical Potential
Stuart Barnscher
Preclinical
Tumor Models Summit
January 29, 2026
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
Preclinical
Tumor Models Summit
January 29, 2026
Advancing ZW209 Trispecific Design with In Vitro & In Vivo Models to Improve DLL3-Directed Responses
Hernaez et al.
Preclinical
PepTalk
January 22, 2026
Engineering Next-Generation T Cell Engagers: A Trispecific Platform for Cancer Immunotherapy
Clinical
ASCO GI
January 9, 2026
A Phase 1, First-in-Human, Multicenter Study of ZW251, a Novel Glypican-3 (GPC3)-Targeted Antibody-Drug Conjugate (ADC), in Participants With Hepatocellular Carcinoma (HCC)
Chandana et al.